Online Message
After receiving your message, our professional team will contact you shortly.
Tumor Efficacy Evaluation
-
Oncology overviewOncology Service HighlightCustomized and multi-dimensional protocol based on targets
SPF animal facility
License for the use of experimental animals: SYXK (Shanghai) 2022-0028Barrier system: rat, mouseOpen system: rabbitAddress：West side of floor 1, Zone B, No.735 ZipingRoad, PudongNewAreaOncology ServicesSerial number Production Service content Input Output Delivery period 1 In vivo pharmacology Syngeneic model - Candidate compounds
- Positive compounds
- Raw data
- In vivo efficacy evaluation report
4-6 weeks
6-10weeks
(cus-tomized)2 In vivo pharmacology CDX model - Candidate compounds
- Positive compounds
- Raw data
- In vivo efficacy evaluation report
4-6 weeks
6-10weeks
(cus-tomized)3 In vivo
pharmacologyPBMC model - Candidate compounds
- Positive compounds
- Raw data
- In vivo efficacy evaluation report
4-6 weeks
6-10weeks
(cus-tomized)4 In vivo
pharmacologyTransgenic mice
model- Candidate compounds
- Positive compounds
- Raw data
- In vivo efficacy evaluation report
4-6 weeks
6-10weeks
(cus-tomized)5 Pharmacological
testFACS assays - Tumor samples
- Peripheral blood
FACS assay
reportOne week 6 Pharmacological
testCytokine assays - Tumor samples
- Peripheral blood
Cytokine assays
reportOne week 7 Pharmacological
testHematology test - Tumor samples
- Peripheral blood
Hematology test
reportOne week 8 Pharmacological
testPathological
test- Tumor samples
- Animal organ samples
- Scanned image of sample
- Pathological test report
2-3 weeks
4-5 weeks
(cus-tomized) -
Preclinical Oncology ModelsSyngeneic
model30 + models validated for antibody and small moleculeLeukemia, breast, lung, colon, melanoma, kidney, bladder and liver etc.CDX
modelNude, NOD-SCID, and NSG model availableLeukemia, breast, lung, colon, skin, pancreatic, stomach, ovary, prostate and liver etc.Humanized
modelhPBMC modelmPBMC modelhCD34 modelKI + hCD34 modelHumanized
tumor cellHumanized cellCell lines: (50 + available)Reliable cell supplyTransgenic mice:
Biocytogen
Genpharma
CyagenIVIS
platformSystemic models available in houseMetastasis and orthotopic modelsMultiple Luc-cell lines availableTissue distribution studies provide reliable results -
Syngeneic modelsList Of Syngeneic Models
Cell line Tissue Disease Mouse strain Available models MC38 colon colorectal
carcinomaC57BL/6 subcutaneous CT-26 large intestine colorectal carcinoma BALB/C subcutaneous 4T1 mammary gland breast cancer BALB/C subcutaneous
orthotopicEL4 T lymphocyte lymphoma C57BL/6 subcutaneous E0771 mammary gland breast carcinoma C57BL/6 subcutaneous LLC lung lung carcinoma C57BL/6 subcutaneous B16F10 skin melanoma C57BL/6 subcutaneous
metastasis(i.v.)ROR1-B16F10 skin melanoma C57BL/6 subcutaneous Pan02 pancreas adenocarcinoma C57BL/6 subcutaneous Growth Curves of Syngeneic Mouse Model
-
CDX ModelsList Of CDX Models
Cell line Tissue Disease Mouse strain Available models HT-29 colon colorectal
adenocarcinomanude subcutaneous NCI-N87 stomach gastric carcinoma nude subcutaneous NCI-H1975 lung NSCLC nude subcutaneous JIMT-1 breast breast carcinoma nude subcutaneous HCT116 colon colorectal carcinoma nude,NSG subcutaneous Colo205 colon colorectal adenocarcinoma nude subcutaneous NCI-H1581 lung NSCLC nude subcutaneous Hep-2 larynx carcinoma nude subcutaneous Detroit 562 pharynx pharyngeal carcinoma NKG subcutaneous SW48 colon colorectal adenocarcinoma NOD SCID subcutaneous PC-3 Lung lung adenocarcinoma nude subcutaneous 22RV1 Prostate carcinoma nude subcutaneous SK-OV-3 ovary adenocarcinoma nude subcutaneous U-87 MG brain glioblastoma NOD SCID subcutaneous
orthotopicA375 skin malignant melanoma NSG subcutaneous Growth Curves of CDX Model
Efficacy Study in NCI-N87 Xenograft Model
ConclusionNo body weight loss was observed during observation. Data are presented as Mean±SEM
Superior tumor suppression was observed in the HER2-positive NCI-N87 xenograft model treated with Trastuzumab
-
PBMC-humanized modelsPBMC ModelsPBMC-transfer induced humanized mouse model
-
PBMC sources
Human Genetic Resources
Chinese and foreigner
PBMC Characterization
-
Mice
NSG/NCG/NOG
B-NDG
NSG- SGM3
NSG-IL15
-
Reconstruction
s.c mix & i.v
Day -14/-10/-2/2
-
Tumor
TME analysis
Biomarker analysis
Cytokine analysis
-
-
IVIS platformIVIS for Orthotopic and Metastatic Models
IVIS case studiesVariety of Luc-cell lines available(70+ cell lines)
IVIS collaboration studies on-going
-
IHC Staining and drug-resistant cellsIHC Staining for targets in mouse and Human tumor samplesImmunohistochemistry Staining
HE
Ki67
CD31
HER2
EGFR
TROP2Biomarker, tumor antigen and receptor staining and bi-staining
Cytokines, chemokines, transcription factor and antibody detections
Customized Biomarkers for cell typing in lymphocytes, NK cells, macrophages, and neutrophils
Drug-resistant Cell LinesCategories Targets SOC Tumor cell Chemotherapy Chemotherapy Docetaxel SNU-16、22RV1、A549、NCI-H1299、KYSE150、KYSE520、AGS、MDA-MB-231 Cisplatin A2780、A549、NCI-H1299、Cal-27、KYSE30、KYSE150、KYSE520、AGS、HT-29、MDA-MB-231 Doxorubicin OVCAR8、NALM6 Oxaliplatin HGC-27、AGS Target therapy EGFR Gifitinib PC-9、HCC827 Osimertinib NCI-H1975、HCC-827、PC-9 C-met Savolitinib
Crizotinib
SavolitinibHs746T、NCI-H1993 ROS1/ALK Lorlatinib NCI-H3122 PARP Niraparib SK-OV-3 ADC HER2 Enhertu
(DS8201)HCC-827、KYSE150、NCI-N87
This site uses cookies and your privacy choices are important to us
We use cookies to improve the user experience and to analyze website traffic. By clicking "Accept", you consent to the use of cookies on our website, such as cookies policies.